Skip to content
← Full study record

NCT03881488 · MORE INFO

Limitations, agreements, and source contact

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies · Source last updated 2026-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
PI agrees to withhold publication until after first multi-center publication or 18 months following study completion, whichever comes first. Additionally, the sponsor can review the results communications prior to public release and can embargo communications regarding the trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ctx-471-001@compasstherapeutics.com
organization
Compass Therapeutics
phone
+1-617-500-8099
title
Clinical Study Lead
Complete source fields
certain Agreement
other Details
PI agrees to withhold publication until after first multi-center publication or 18 months following study completion, whichever comes first. Additionally, the sponsor can review the results communications prior to public release and can embargo communications regarding the trial results for a period that is more than 60 days but less than or equal to 180 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
point Of Contact
email
ctx-471-001@compasstherapeutics.com
organization
Compass Therapeutics
phone
+1-617-500-8099
title
Clinical Study Lead

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice